SCHEMBL925336

SCHEMBL925336

CCCCCCCCCCCCn1c(=O)[nH]c(=O)c2c1=NC(=O)N=2

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HTT P42858 3/20 0.45
▸ MAPK10 P53779 1/20 0.45
▸ TSHR P16473 5/20 0.42
▸ MAPK1 P28482 3/20 0.42
▸ HPGD P15428 2/20 0.42
▸ LMNA P02545 2/20 0.42
▸ SMN1; SMN2 Q16637 1/20 0.42
▸ MAPT P10636 2/20 0.42
▸ ATM Q13315 1/20 0.42
▸ PDE4A P27815 1/20 0.42
▸ ADORA2A P29274 1/20 0.42
▸ PDE4B Q07343 1/20 0.42
▸ PDE4C Q08493 1/20 0.42
▸ PDE4D Q08499 1/20 0.42
▸ ALDH1A1 P00352 4/20 0.41
▸ MEN1 O00255 3/20 0.41
▸ KMT2A Q03164 3/20 0.41
▸ XBP1 P17861 2/20 0.41
▸ TP53 P04637 1/20 0.40
▸ RAB9A P51151 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6189315 0.72 TNF (0.49) HTTTSHRMAPK1LMNASMN1; SMN2
SCHEMBL4954143 0.70 HTT (0.49) HTTMAPK10TSHRMAPK1HPGD
SCHEMBL4105918 0.70 HTT (0.49) HTTMAPK10TSHRMAPK1HPGD
SCHEMBL31098153 0.70 HTT (0.49) HTTMAPK10TSHRSMN1; SMN2MAPT
SCHEMBL11357728 0.70 HTT (0.49) HTTMAPK10TSHRMAPK1HPGD
SCHEMBL11364443 0.70 HTT (0.49) HTTMAPK10TSHRMAPK1HPGD
SCHEMBL19336852 0.70 HTT (0.49) HTTMAPK10TSHRSMN1; SMN2MAPT
SCHEMBL678855 0.70 HTT (0.49) HTTMAPK10TSHRMAPK1HPGD
SCHEMBL7749303 0.70 HTT (0.49) HTTMAPK10TSHRMAPK1HPGD
SCHEMBL11359991 0.70 HTT (0.49) HTTMAPK10TSHRMAPK1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-1275511-A — — None — — JP disclosed
US-7875620-B2 administering uric acid or lithium urate for treating a microbacterial infection(bacteriocidal or bacteriostatic) caused by staphylococcus aureus and streptococcus pyogenes PIPER MEDICAL, INC. (US) 2011-01-25 — — US disclosed
EP-0987009-B1 Aqueous cosmetic composition containing stably solubilized uric acid and amphoteric surfactant and method for stably solubilizing uric acid in aqueous cosmetic composition SCHWARZKOPF & HENKEL K K (JP) 2008-10-08 — — EP disclosed
US-20070003590-A1 Methods of Treating Microbial Infections PIPER MEDICAL, INC. 2007-01-04 — — US disclosed
EP-0875241-B1 Aqueous cosmetic composition containing stably solubilized uric acid and water-soluble polymer and method for stably solubilizing uric acid in aqueous cosmetic composition HENKEL LION COSMETICS CO LTD (JP) 2004-12-01 — — EP disclosed
CN-1118276-C Aqueous cosmetic composition contg. stably solubilized uric acid and water-soluble polymer and method for stably solubilizing uric acid in aqueous cosmetic composition YAMAHATSU SANGYO KASHA LTD (JP) 2003-08-20 — — CN disclosed
EP-0987009-A1 Aqueous cosmetic composition containing stably solubilized uric acid and amphoteric surfactant and method for stably solubilizing uric acid in aqueous cosmetic composition YAMAHATSU SANGYO KAISHA, LTD. (JP) 2000-03-22 — — EP disclosed
US-6027719-A A STABLY-SOLUBILIZED URIC ACID IN AN AQUEOUS COSMETIC COMPOSITION INCLUDING AN ACRYLIC ACID/ALKYL (METH)ACRYLATE COPOLYMER OR A (METH)ACRYLIC ACID/POLYOXYETHYLENE GLYCOL COPOLYMER; PH ADJUSTED TO ALKALINE CONDITIONS; HAIR; SKIN; YAMAHATSU SANGYO KAISHA, LTD. (JP) 2000-02-22 — — US disclosed
CN-1200264-A Aqueous cosmetic composition contg. stably solubilized uric acid and water-soluble polymer and method for stably solubilizing uric acid in aqueous cosmetic composition YAMAHATSU SANGYO KASHA LTD (JP) 1998-12-02 — — CN disclosed
US-5833969-A BETAINE DERIVATIVE SURFACTANTS; HAIR DYES YAMAHATSU SANGYO KAISHA, LTD. (JP) 1998-11-10 — — US disclosed
EP-0875241-A2 Aqueous cosmetic composition containing stably solubilized uric acid and water-soluble polymer and method for stably solubilizing uric acid in aqueous cosmetic composition YAMAHATSU SANGYO KAISHA, LTD. (JP) 1998-11-04 — — EP disclosed
JP-H01275511-A EXTERNAL DRUG FOR SKIN SHISEIDO CO LTD 1989-11-06 — — JP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070003590-A1 Methods of Treating Microbial Infections XDH, MSR1, FPR3 HTT 4201/4885MAPK10 3959/4885TSHR 1079/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback